Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 1.653
Filtrer
1.
Medicine (Baltimore) ; 103(37): e39633, 2024 Sep 13.
Article de Anglais | MEDLINE | ID: mdl-39287238

RÉSUMÉ

BACKGROUND: Retroperitoneal liposarcoma is a rare and complex tumor originating from the mesenchymal tissues, with no specific manifestations in the early stage, and a large tumor size in the late stage. Patients often consult a physician because of large abdominal mass, increased abdominal circumference, and abdominal pain, and rarely because of leukocytosis. PATIENT CONCERNS: A 54-year-old female presented to our hospital with complaints of "abdominal distension for over 3 months, left lumbar pain for over 2 months." Considering the comprehensive symptoms, examinations, computed tomography scans, and pathological results, the possibility of retroperitoneal liposarcoma is high. DIAGNOSES: Retroperitoneal liposarcoma with leukocytosis. INTERVENTIONS: Open retroperitoneal mass excision along with transcystoscopic left ureteral Double-J Ureterl Stent Insertion tube placement and left nephrectomy. OUTCOMES: The postoperative pathological findings of the abdominal mass, combined with morphological and immunohistochemical results, are consistent with retroperitoneal liposarcoma. The patient had no recurrence in 7 months of postoperative follow-up conducted on the telephone and is now in continued follow-up. CONCLUSION: Retroperitoneal liposarcoma is highly malignant and prone to recurrence. Radical surgery is currently the primary treatment modality for patients with this condition. Analogous to cancer patients, those with elevated white blood cell counts and retroperitoneal liposarcoma may have poor prognoses, with a high likelihood of local recurrence and distant metastasis. Close postoperative follow-up is necessary. Therefore, regular postoperative review of blood routine may be a relatively economical and convenient method for the early detection of recurrence and metastasis of retroperitoneal liposarcoma.


Sujet(s)
Liposarcome , Tumeurs du rétropéritoine , Humains , Tumeurs du rétropéritoine/chirurgie , Tumeurs du rétropéritoine/diagnostic , Tumeurs du rétropéritoine/anatomopathologie , Liposarcome/chirurgie , Liposarcome/anatomopathologie , Liposarcome/diagnostic , Adulte d'âge moyen , Femelle , Tomodensitométrie , Néphrectomie/méthodes , Hyperleucocytose/étiologie
4.
Chin Clin Oncol ; 13(3): 42, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38859609

RÉSUMÉ

BACKGROUND: Neutrophilia is an increase in the number of neutrophils over 7.5×103/µL. An increase in leukocytes over 50×103/µL is called a leukemoid reaction; and when it is associated with a solid tumor, it is considered a paraneoplastic syndrome called paraneoplastic leukemoid reaction (PLR). It is a very rare clinical condition and it is very unusual for it to be associated with carcinosarcoma. We present two cases of a leukemoid reaction observed in the Medical Oncology Department of the University Hospital of Salamanca between May and September 2023. The main objectives of our article are to describe the unusual appearance of paraneoplastic leukocytosis at the diagnosis of carcinosarcoma carcinosarcoma, explain in a detailed way its diagnostic procedure and to show the poor prognosis to which it is associated. CASE DESCRIPTION: In our presentation, we describe two similar cases: first of all, a 60-year-old woman without relevant medical history. She was referred by her primary physician to the Department of Internal Medicine in August 2023 with asthenia, lumbar pain, and weight loss of 12 kg of 3 months of evolution. The physical examination revealed a palpable hypogastric mass. An abdominal, pelvic, and thoracic computed tomography (CT) scan revealed a heterogenous solid mass with necrotic areas originating in the uterus. The anatomopathological diagnosis was carcinosarcoma. The patient showed a progressive worsening in her renal function associated with hyperviscosity secondary to hyperleukocytosis caused by 170×103/µL neutrophils. In the second case we describe the diagnosis of a PLR secondary to a kidney carcinosarcoma. When the patient started chemotherapy, he presented 55.08×103/µL leukocytes, 53.16×103/µL neutrophils. Eight days after receiving chemotherapy, the patient was admitted as an emergency with oligoanuria and decreased consciousness. He presented creatinine 6.25 mg/dL, phosphate 12.4 mg/dL, leukocytes 1.05×103/µL, and neutrophils 0.71×103/µL. The clinical diagnosis was acute exacerbation of multifactorial mixed (renal and prerenal) chronic kidney disease associated with tumor lysis syndrome and grade 3 neutropenia. The patient presented a poor evolution, dying after 2 months. CONCLUSIONS: PLR is a severe paraneoplastic syndrome associated with different types of solid tumors. Its appearance at the time of diagnosis of a tumor implies a poor vital prognosis.


Sujet(s)
Carcinosarcome , Hyperleucocytose , Syndromes paranéoplasiques , Humains , Carcinosarcome/complications , Femelle , Adulte d'âge moyen , Hyperleucocytose/étiologie , Hyperleucocytose/complications , Syndromes paranéoplasiques/étiologie , Mâle
6.
Int J Hematol ; 120(2): 252-255, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38796826

RÉSUMÉ

B-cell prolymphocytic leukemia (B-PLL) was recognized as a distinct entity in the fourth edition of the World Health Organization (WHO) classification for hematolymphoid neoplasms (WHO-HAEM4); however, its de novo presentation has been removed from the upcoming 5th edition classification (WHO-HAEM5). We present a case of a 65-year-old man with leukocytosis, fatigue, and no organomegaly by imaging. Bone marrow examination showed a prolymphocytoid population comprising 78% of the marrow elements. After thorough exclusion of other entities by clinical parameters and ancillary methods, we concluded that this case represents a de novo case of B-PLL.


Sujet(s)
Leucémie prolymphocytaire à cellules B , Humains , Mâle , Sujet âgé , Leucémie prolymphocytaire à cellules B/anatomopathologie , Leucémie prolymphocytaire à cellules B/diagnostic , Moelle osseuse/anatomopathologie , Hyperleucocytose/diagnostic , Hyperleucocytose/étiologie , Hyperleucocytose/anatomopathologie
8.
Oral Maxillofac Surg ; 28(3): 1399-1404, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-38418701

RÉSUMÉ

We describe a case of mandibular gingival carcinoma with hypercalcaemia and leukocytosis caused by tumour-derived parathyroid hormone-related protein (PTHrP) and granulocyte colony-stimulating factor (G-CSF). A 54-year-old man presented to our Department of Oral and Maxillofacial Surgery with a chief complaint of a left-sided mandibular gingival ulcer. A 42 mm × 20 mm sized ulcer was found on the left lower molar gingiva. Squamous cell carcinoma was pathologically diagnosed. The patient underwent a hemimandibulectomy, left-sided radical neck dissection, plate reconstruction, pectoralis major musculocutaneous flap reconstruction, and tracheostomy under general anaesthesia. Pathologically, two metastatic lymph nodes were identified. Residual tumour was suspected at the resection margins. Eight weeks after surgery, the patient started postoperative concurrent chemoradiotherapy (CCRT). Two weeks after CCRT, the patient developed hypercalcaemia. Serum levels of PTHrP and G-CSF increased in parallel with the progression of hypercalcaemia and leukocytosis. Immunohistochemical analysis of the surgical specimen showed positivity for G-CSF. Based on these clinical and pathological findings, the patient was diagnosed with hypercalcaemia and leukocytosis associated with malignancy and was treated with denosumab. Irradiation was terminated at 50 Gy because CT showed rapid disease progression. Chemotherapy was initiated, however, four weeks after the start of chemotherapy, a CT scan showed increased metastases and pleural dissemination. Therefore, chemotherapy was discontinued. One week after the chemotherapy was discontinued, the patient died of respiratory failure.


Sujet(s)
Carcinome épidermoïde , Tumeur de la gencive , Facteur de stimulation des colonies de granulocytes , Protéine apparentée à l'hormone parathyroïdienne , Humains , Mâle , Adulte d'âge moyen , Tumeur de la gencive/anatomopathologie , Tumeur de la gencive/chirurgie , Carcinome épidermoïde/anatomopathologie , Hyperleucocytose/étiologie , Hypercalcémie/étiologie , Issue fatale , Tumeurs de la mandibule/anatomopathologie , Tumeurs de la mandibule/chirurgie
9.
Int J Hematol ; 119(5): 495-504, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38421488

RÉSUMÉ

Patients with cancer have a higher risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), compared to the general population. Cancer-associated thrombosis (CAT) is a thrombotic event that occurs as a complication of cancer or cancer therapy. Major factors determining VTE risk in cancer patients include not only treatment history and patient characteristics, but also cancer type and site. Cancer types can be broadly divided into three groups based on VTE risk: high risk (pancreatic, ovarian, brain, stomach, gynecologic, and hematologic), intermediate risk (colon and lung), and low risk (breast and prostate). This implies that the mechanism of VTE differs between cancer types and that specific VTE pathways may exist for different cancer types. This review summarizes the specific pathways that contribute to VTE in cancer patients, with a particular focus on leukocytosis, neutrophil extracellular traps (NETs), tissue factor (TF), thrombocytosis, podoplanin (PDPN), plasminogen activator inhibitor-1 (PAI-1), the intrinsic coagulation pathway, and von Willebrand factor (VWF).


Sujet(s)
Tumeurs , Thrombose , Humains , Tumeurs/complications , Thrombose/étiologie , Pièges extracellulaires/métabolisme , Thromboembolisme veineux/étiologie , Facteurs de risque , Coagulation sanguine , Thromboplastine/métabolisme , Hyperleucocytose/étiologie
10.
Gut Liver ; 18(1): 40-49, 2024 Jan 15.
Article de Anglais | MEDLINE | ID: mdl-37161697

RÉSUMÉ

Background/Aims: Delayed perforation is a rare but serious adverse event of gastric endoscopic submucosal dissection (ESD). The aim of this study was to clarify the clinical features and appropriate management strategy of patients with delayed perforation. Methods: Among 11,531 patients who underwent gastric ESD, the clinical features and outcomes of patients who experienced delayed perforation were retrospectively reviewed and compared with those of the control group. Results: Delayed perforation occurred in 15 of 11,531 patients (0.13%). The patients with delayed perforation were significantly older than those without delayed perforation (p=0.027). The median time to diagnosis of delayed perforation was 28.8 hours (range, 14 to 71 hours). All 15 patients with delayed perforation complained of severe abdominal pain after gastric ESD and underwent subsequent chest X-rays (CXRs) for evaluation. In subsequent CXR, free air was found in 12 patients (80%). For three (20%) patients without free air in CXR, delayed perforation was finally diagnosed by computed tomography. Leukocytosis was significantly less frequent in the patients without free air in CXR (p=0.022). A perforation hole smaller than 1 cm in size was more frequently observed in the six patients who underwent successful non-surgical treatments than in the nine patients who underwent surgery (p<0.001). There was no mortality related to delayed perforation. Conclusions: One-fifth of the patients with delayed perforation did not show free air in CXR and exhibited less leukocytosis than those with free air. Non-surgical treatments including endoscopic closure might be considered as an initial treatment modality for delayed perforation smaller than 1 cm.


Sujet(s)
Mucosectomie endoscopique , Tumeurs de l'estomac , Humains , Mucosectomie endoscopique/effets indésirables , Mucosectomie endoscopique/méthodes , Études rétrospectives , Hyperleucocytose/étiologie , Tumeurs de l'estomac/chirurgie , Tumeurs de l'estomac/étiologie , Résultat thérapeutique
11.
CEN Case Rep ; 13(1): 45-52, 2024 02.
Article de Anglais | MEDLINE | ID: mdl-37227595

RÉSUMÉ

Systemic effects associated with hormones and cytokines secreted by tumor cells can cause paraneoplastic syndrome. Leukemoid reactions and hypercalcemia are relatively common manifestations of paraneoplastic syndrome. Here, we describe the case of a 90-year-old woman who presented with leukocytosis and hypercalcemia and was diagnosed with granulocyte-colony stimulating factor (G-CSF)-producing cervical cancer with elevated levels of parathyroid hormone-related protein (PTHrP). The patient visited our hospital complaining of general fatigue and anorexia. On admission, she presented with marked leukocytosis, hypercalcemia, and an increase in C-reactive protein level. On the basis of abdominal magnetic resonance imaging and histopathological examination, the patient was diagnosed with cervical cancer. Additional tests confirmed elevated plasma levels of G-CSF, PTHrP, and serum interleukin-6. Immunostaining of pathological specimens of the uterine cervix showed expression of G-CSF in tumor cells. The patient was diagnosed with G-CSF-producing cervical cancer accompanied by elevation of PTHrP levels. As a treatment for hypercalcemia, discontinuation of oral vitamin D derivative and administration of saline and elcatonin were ineffective, and therapeutic intervention with zoledronic acid hydrate was required. Considering the patient's advanced age, surgical resection of cervical cancer was not performed. She died from congestive heart failure approximately 3 months after hospitalization. This case was indicated to be a paraneoplastic syndrome in which G-CSF and PTHrP-induced leukocytosis and hypercalcemia. To the best of our knowledge, there have been no reports of G-CSF-producing cervical cancer with elevated PTHrP levels, and our case is the first report.


Sujet(s)
Hypercalcémie , Syndromes paranéoplasiques , Tumeurs du col de l'utérus , Humains , Femelle , Sujet âgé de 80 ans ou plus , Protéine apparentée à l'hormone parathyroïdienne , Facteur de stimulation des colonies de granulocytes/usage thérapeutique , Hypercalcémie/complications , Tumeurs du col de l'utérus/complications , Hyperleucocytose/étiologie , Syndromes paranéoplasiques/étiologie , Syndromes paranéoplasiques/complications , Granulocytes/métabolisme
13.
Cancer ; 129(12): 1873-1884, 2023 06 15.
Article de Anglais | MEDLINE | ID: mdl-36943896

RÉSUMÉ

BACKGROUND: Hyperleukocytosis in patients with acute myeloid leukemia (AML) has been associated with worse outcomes. For cytoreduction, leukapheresis has been used but its clinical utility is unknown, and low-dose cytarabine (LD-cytarabine) is used as an alternative method. METHODS: Children with newly diagnosed AML treated between 1997 and 2017 in institutional protocols were studied. Hyperleukocytosis was defined as a leukocyte count of ≥100 × 109 /L at diagnosis. Clinical characteristics, early complications, survival data, and effects of cytoreductive methods were reviewed. Among 324 children with newly diagnosed AML, 49 (15.1%) presented with hyperleukocytosis. Initial management of hyperleukocytosis included leukapheresis or exchange transfusion (n = 16, considered as one group), LD-cytarabine (n = 18), hydroxyurea (n = 1), and no leukoreduction (n = 14). RESULTS: Compared with patients who received leukapheresis, the percentage decrease in leukocyte counts following intervention was greater among those who received LD-cytarabine (48% vs. 75%; p = .02), with longer median time from diagnosis to initiation of protocol therapy (28.1 vs. 95.2 hours; p < .001). The incidence of infection was higher in patients (38%) who had leukapheresis than those who receive LD-cytarabine (0%) or leukoreduction with protocol therapy (14%) (p = .008). No differences were noted in the outcomes among the intervention groups. Although patients with hyperleukocytosis had higher incidences of pulmonary and metabolic complications than did those without, no early deaths occurred, and the complete remission, event-free survival, overall survival rates, and outcomes of both groups were similar. CONCLUSION: LD-cytarabine treatment appears to be a safe and effective means of cytoreduction for children with AML and hyperleukocytosis.


Sujet(s)
Interventions chirurgicales de cytoréduction , Leucémie aigüe myéloïde , Humains , Enfant , Interventions chirurgicales de cytoréduction/effets indésirables , Hyperleucocytose/thérapie , Hyperleucocytose/épidémiologie , Hyperleucocytose/étiologie , Leucémie aigüe myéloïde/complications , Leucémie aigüe myéloïde/thérapie , Leucémie aigüe myéloïde/diagnostic , Numération des leucocytes , Leucaphérèse/méthodes , Cytarabine
17.
Endocr J ; 70(4): 375-384, 2023 Apr 28.
Article de Anglais | MEDLINE | ID: mdl-36543188

RÉSUMÉ

A 61-year-old Japanese woman presented with epigastric pain and jaundice. Imaging showed the presence of primary distal cholangiocarcinoma (DCC). A subtotal stomach-preserving pancreaticoduodenectomy was performed, followed by chemotherapy using S-1. However, second-line chemotherapy with gemcitabine and cis-diamminedichloroplatinum was required for the treatment of hepatic metastasis of the DCC 3 months following the surgery. Nine months after the surgery, the serum calcium and parathyroid hormone-related peptide concentrations were high, at 16.5 mg/dL and 28.7 pmol/L, respectively, which suggested the presence of humoral hypercalcemia of malignancy (HHM) secondary to the DCC. Moreover, marked leukocytosis, with a white blood cell count of 40,400/µL, was also present. The patient died 11 months after the diagnosis of DCC. Because hypercalcemia of malignancy is associated with a poor prognosis, and HHM and leukocytosis caused by DCC are very rare, we have presented the present case in detail and provide a review of the existing literature.


Sujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Hypercalcémie , Femelle , Humains , Adulte d'âge moyen , Hypercalcémie/étiologie , Hyperleucocytose/étiologie , Cholangiocarcinome/complications , Cholangiocarcinome/diagnostic , Cholangiocarcinome/chirurgie , Tumeurs des canaux biliaires/complications , Tumeurs des canaux biliaires/diagnostic , Tumeurs des canaux biliaires/chirurgie , Conduits biliaires intrahépatiques
18.
J Am Coll Surg ; 236(6): 1181-1187, 2023 06 01.
Article de Anglais | MEDLINE | ID: mdl-36503868

RÉSUMÉ

BACKGROUND: The objective of this study was to evaluate the clinical utility of a routine predischarge WBC count (RPD-WBC) for predicting postdischarge organ space infection (OSI) in children with complicated appendicitis. STUDY DESIGN: This was a multicenter study using NSQIP-Pediatric data from 14 hospitals augmented with RPD-WBC data obtained through supplemental chart review. Children with fever or surgical site infection diagnosed during the index admission were excluded. The positive predictive value (PPV) for postdischarge OSI was calculated for RPD-WBC values of persistent leukocytosis (≥9.0 × 10 3 cells/µL), increasing leukocytosis (RPD-WBC > preoperative WBC), quartiles of absolute RPD-WBC, and quartiles of relative proportional change from preoperative WBC. Logistic regression was used to calculate predictive values adjusted for patient age, appendicitis severity, and use of postdischarge antibiotics. RESULTS: A total of 1,264 children were included, of which 348 (27.5%) had a RPD-WBC obtained (hospital range: 0.8 to 100%, p < 0.01). The median RPD-WBC was similar between children who did and did not develop a postdischarge OSI (9.0 vs 8.9; p = 0.57), and leukocytosis was absent in 50% of children who developed a postdischarge OSI. The PPV of RPD-WBC was poor for both persistent and increasing leukocytosis (3.9% and 9.8%, respectively) and for thresholds based on the quartiles of highest RPD-WBC values (>11.1, PPV: 6.4%) and greatest proportional change (<32% decrease from preoperative WBC; PPV: 7.8%). CONCLUSIONS: Routine predischarge WBC data have poor predictive value for identifying children at risk for postdischarge OSI after appendectomy for complicated appendicitis.


Sujet(s)
Appendicite , Humains , Enfant , Appendicite/complications , Appendicite/diagnostic , Appendicite/chirurgie , Hyperleucocytose/diagnostic , Hyperleucocytose/étiologie , Sortie du patient , Post-cure , Numération des leucocytes , Appendicectomie/effets indésirables , Études rétrospectives
19.
Khirurgiia (Mosk) ; (12. Vyp. 2): 26-35, 2022.
Article de Anglais, Russe | MEDLINE | ID: mdl-36562670

RÉSUMÉ

OBJECTIVE: To evaluate the accuracy of clinical, laboratory and instrumental methods for diagnosis of intestinal ischemia following small bowel obstruction in emergency hospitals. MATERIAL AND METHODS: Multiple-center observational retrospective study enrolled 158 consecutive patients with benign small bowel obstruction (SBO) treated at four hospitals between May 2017 and December 2019. The role of clinical, laboratory and instrumental diagnostic methods for intestinal ischemia was analyzed. We assessed the impact of CT and contrast-enhanced X-ray examination on survival of patients. RESULTS: Laboratory parameters as criteria of ischemia following SBO were similar (leukocytosis >14·109/l (p=1.0), serum lactate >2.0 mmol/l (p=0.28), heart rate >90/min (p=0.71) and fever (p=0.74)). The only laboratory indicator with significant differences was serum sodium. Decrease in leukocytosis over time was less common in patients with ischemia (25% vs. 61.3%, p=0.012). Univariate Kaplan-Meier analysis did not establish the effect of CT on survival (7.8% [95% CI 7.6-8.0] vs. 6.5% [95% CI 6.3-6.6], p=0.786). Logistic regression revealed 6.4-fold higher chance of accurate diagnosis (ischemia/non-ischemia) in case of CT-based conclusion of ischemia (95% CI 0.025-0.85). Univariate analysis showed that the use of water-soluble contrast for adhesive SBO was associated with lower mortality (4.1% [95% CI 4.0-4.2] vs. 14.3% [95% CI 13.7-14.9], p=0.032) without assessing the comparability of groups. CONCLUSION: Routine laboratory tests were not specific for intestinal ischemia. Therefore, they should not be considered as the only criteria for surgical tactics in intestinal obstruction. Only CT showed acceptable diagnostic accuracy, and, apparently, only this method has real prospects for improving the quality of diagnosis due to technical support, training of surgeons and specialists for diagnosis.


Sujet(s)
Traumatismes de l'abdomen , Occlusion intestinale , Ischémie mésentérique , Blessures du thorax , Lésions du système vasculaire , Humains , Études rétrospectives , Hyperleucocytose/étiologie , Hyperleucocytose/complications , Tomodensitométrie/méthodes , Occlusion intestinale/diagnostic , Occlusion intestinale/étiologie , Occlusion intestinale/chirurgie , Produits de contraste , Ischémie/diagnostic , Ischémie/étiologie , Ischémie/chirurgie , Traumatismes de l'abdomen/complications , Blessures du thorax/complications
20.
Vnitr Lek ; 68(E-7): 28-35, 2022.
Article de Anglais | MEDLINE | ID: mdl-36402557

RÉSUMÉ

The blood cell count is often examined in routine clinical praxis. Physiologic leucocyte count is in range 4-10 × 109 in liter of blood. Abnormal values of leukocytes and subtypes of leukocytes in differential count are often present. Changes in leukocytes counts are caused by variety of benignant or malignant conditions. It is important in clinical praxis to interpret changes in blood cell count correctly and choose adequate approach in investigation process. In general, leukocytosis and leukocytopenia may present in primary hematologic disorder or secondary/reactive states, caused by reaction of hematopoiesis to underlying condition. This article review common causes of leukocytosis or leucopenia and give basic advice how to investigate patients with changes in leukocytes count.


Sujet(s)
Hyperleucocytose , Leucopénie , Humains , Hyperleucocytose/diagnostic , Hyperleucocytose/étiologie , Diagnostic différentiel , Leucopénie/diagnostic , Leucopénie/complications , Numération des leucocytes
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE